← Leaderboards
Michael Lafleur
Arietis
$15,430,567
Attributed
$21,157,225
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,157,225 · 6
By mechanism
R01$11,453,317 · 3
R44$9,703,908 · 3
Top collaborators
- Richard Edward Lee11 shared
Most similar at Arietis
Same institution · by research overlap
- Richard Edward Lee$36,742,506
- Kenneth Coleman$7,183,423
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoBacteriaDesignStructureResistance DevelopmentPathogenAntibioticsThigh StructureMethicillin Resistant Staphylococcus AureusSolubilityResistancePharmaceutical PreparationsInfectionMicrobial BiofilmsPeptide HydrolasesSafetyIn VitroDrug KineticsResistant StrainPre-ClinicalPreventPharmaceutical ChemistryAnalog
Grant awards (20)
Development of a Dual-Targeting ClpP Activating Antibiotic$1,000,000
R44 · FY2025 · AI · contact PI
Targeting NuoD for the treatment of H. pylori$844,980
R01 · FY2025 · AI
Hybrid Antibiotics for Persistent Infections$832,827
R01 · FY2025 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic$999,619
R44 · FY2024 · AI · contact PI
Targeting NuoD for the treatment of H. pylori$844,980
R01 · FY2024 · AI
Hybrid Antibiotics for Persistent Infections$842,568
R01 · FY2024 · AI
Development of ureadepsipetides for drug-resistant infections$1,186,918
R01 · FY2023 · AI · contact PI
Development of a Dual-Targeting ClpP Activating Antibiotic$1,000,000
R44 · FY2023 · AI · contact PI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic$995,100
R44 · FY2023 · AI · contact PI
Targeting NuoD for the treatment of H. pylori$865,480
R01 · FY2023 · AI
Hybrid Antibiotics for Persistent Infections$860,889
R01 · FY2023 · AI
Development of ureadepsipetides for drug-resistant infections$1,200,871
R01 · FY2022 · AI · contact PI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic$996,046
R44 · FY2022 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,209,617
R01 · FY2021 · AI · contact PI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic$995,100
R44 · FY2021 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,235,145
R01 · FY2020 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,529,042
R01 · FY2019 · AI · contact PI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,248,159
R44 · FY2018 · AI · contact PI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,251,577
R44 · FY2017 · AI · contact PI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,218,307
R44 · FY2016 · AI · contact PI